Utama › Rabdomiosarkoma
Kajian klinikal Rabdomiosarkoma sedang mengambil peserta di AS
26 kajian untuk Rabdomiosarkoma sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Houston, TX6 kajian
- Memphis, TN6 kajian
- Washington, DC5 kajian
- Salt Lake City, UT4 kajian
- Philadelphia, PA4 kajian
- Boston, MA4 kajian
- Seattle, WA3 kajian
- Aurora, CO3 kajian
- Dallas, TX3 kajian
- Birmingham, AL3 kajian
- The Bronx, NY3 kajian
- Baltimore, MD3 kajian
Mengikut negeri
- Alabama3 kajian
- California7 kajian
- Colorado3 kajian
- Florida3 kajian
- Maryland4 kajian
- Massachusetts4 kajian
- New York4 kajian
- Ohio5 kajian
- Pennsylvania5 kajian
- Tennessee8 kajian
- Texas9 kajian
- Utah4 kajian
- Washington3 kajian
- Wilayah Columbia4 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Mengambil pesertaFasa 1
Umur 3 hingga 39 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Mengambil pesertaFasa 1
24 Months – 18 Years · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Mengambil pesertaFasa 1/2
Sehingga umur 30 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Mengambil pesertaFasa 3
Sehingga umur 50 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Mengambil peserta
Semua umur · Semua jantina · Dikemas kini 21 Ogo 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Mengambil pesertaFasa 1
Umur 1 hingga 23 · Semua jantina · Dikemas kini 13 Ogo 2026 · NCT07172958Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT05210374Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Mengambil pesertaFasa 1
Umur 1 hingga 21 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT04715191Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Mengambil pesertaFasa awal 1
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Mengambil pesertaFasa 1/2
Umur 1 hingga 30 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Mengambil peserta
Sehingga umur 39 · Semua jantina · Dikemas kini 13 Jul 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Mengambil pesertaFasa 1/2
6 Months – 25 Years · Semua jantina · Dikemas kini 30 Jun 2026 · NCT06625190Familial Investigations of Childhood Cancer Predisposition
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 17 Jun 2026 · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Mengambil pesertaFasa 2
Sehingga umur 22 · Semua jantina · Dikemas kini 15 Jun 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Mengambil pesertaFasa 1/2
6 Months – 30 Years · Semua jantina · Dikemas kini 2 Jun 2026 · NCT04796012B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Mengambil pesertaFasa 1
Sehingga umur 21 · Semua jantina · Dikemas kini 19 Mei 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 19 Mei 2026 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Mengambil pesertaFasa 1
Umur 1 hingga 30 · Semua jantina · Dikemas kini 15 Apr 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Mengambil pesertaFasa 2
Umur 1 hingga 50 · Semua jantina · Dikemas kini 13 Mac 2026 · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Mengambil pesertaFasa 1/2
Umur 12 hingga 49 · Semua jantina · Dikemas kini 19 Feb 2026 · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Mengambil pesertaFasa 1
Umur 1 hingga 26 · Semua jantina · Dikemas kini 17 Feb 2026 · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Mengambil pesertaFasa 1
Umur 1 hingga 25 · Semua jantina · Dikemas kini 22 Jan 2026 · NCT04995003Molecular Analysis Of Solid Tumors
Mengambil pesertaKajian pemerhatian
Sehingga umur 25 · Semua jantina · Dikemas kini 12 Nov 2025 · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Mengambil pesertaFasa 1
Sehingga umur 21 · Semua jantina · Dikemas kini 3 Nov 2025 · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Mengambil pesertaFasa 1
7 Months – 21 Years · Semua jantina · Dikemas kini 16 Okt 2025 · NCT02508038Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.